FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562165295> ?p ?o ?g. }

• W2562165295 abstract "Abstract Introduction: Lenalidomide (L) is an immunomodulatory agent (IMiD®), recently approved for treatment of patients (pts) with previously treated multiple myeloma and del 5q- MDS. Its antitumor effects are reported to be mediated at least in part through modulation of both the cytokine and the immune cellular tumor microenvironment. Clinical efficacy of L in pts with B-CLL has not been investigated previously. In a phase II clinical study, we examined the antileukemic effects of L in pts with relapse (rel) or refractory (ref) B-CLL. Patients and Methods: CLL pts with rel or ref disease were eligible. L was given at 25mg PO QD from days 1–21 of 28-day cycle. Response was assessed every month using the NCI-WG 1996 criteria. Treatment with L was continued until progressive disease (PD) or molecular complete response (CR). Pts with PD received rituximab (R) (375mg/m2) with L. Target enrollment was 45 patients. Results: Forty-five pts, median age of 64 years (range: 42–75) were enrolled. Advance stage disease was noted in 64%, elevated B2M in 24% and fludarabine refractory disease in 51% of the pts. Pts had a median of 3 prior therapies (range 1–10). All pts are evaluable for toxicity. Thrombocytopenia and neutropenia were the most common hematologic toxicity while fatigue and flare reaction (sudden, tender enlargement of lymph node, liver and/or spleen, with or without rash, low grade fever and/or increase in white blood counts) were the most common non-hematologic complications. Two patients experience reversible tumor lysis syndrome. On an intent-to-treat analysis, overall response rate was 42% with complete remission in 9% (n=4) and partial remission in 33% (n=15) of the pts. Molecular complete response (determined by PCR) was noted in 3 pts. Twelve pts were inevaluable (unable to complete 2 treatment cycles; either for toxicity or consent withdrawal) 4 are too early for response evaluation. Response rate among evaluable patients was 65.5% (19/29). To date only 2 pts have required the addition of R to L due to PD. Both have achieved a PR with combination therapy. Correlative studies: we evaluated baseline T and NK cell repertoire, modulation of cytokines (VEGF, IL-10, IL-6, TNF-alpha) as well as modulation of gene expression profiles before and after treatment with L, this data will be presented at the meeting. Conclusion: L is clinically active in pts with rel/ref CLL. CR’s, as well as, molecular CR determined by PCR were achieved with single agent L. Interestingly, in pts who developed resistance to L alone, addition of R resulted in a clinical response. These results are exciting and warrant further investigation of L in CLL pts. Final results of this study will be presented at the meeting." @default.
• W2562165295 created "2017-01-06" @default.
• W2562165295 creator A5001276253 @default.
• W2562165295 creator A5006011014 @default.
• W2562165295 creator A5010286156 @default.
• W2562165295 creator A5011706295 @default.
• W2562165295 creator A5019624678 @default.
• W2562165295 creator A5022068541 @default.
• W2562165295 creator A5025865972 @default.
• W2562165295 creator A5035939523 @default.
• W2562165295 creator A5043136547 @default.
• W2562165295 creator A5091651670 @default.
• W2562165295 creator A5091653815 @default.
• W2562165295 date "2006-11-16" @default.
• W2562165295 modified "2023-09-28" @default.
• W2562165295 title "Clinical Efficacy of Lenalidomide {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase II Clinical Trial." @default.
• W2562165295 doi "https://doi.org/10.1182/blood.v108.11.306.306" @default.
• W2562165295 hasPublicationYear "2006" @default.
• W2562165295 type Work @default.
• W2562165295 sameAs 2562165295 @default.
• W2562165295 citedByCount "5" @default.
• W2562165295 crossrefType "journal-article" @default.
• W2562165295 hasAuthorship W2562165295A5001276253 @default.
• W2562165295 hasAuthorship W2562165295A5006011014 @default.
• W2562165295 hasAuthorship W2562165295A5010286156 @default.
• W2562165295 hasAuthorship W2562165295A5011706295 @default.
• W2562165295 hasAuthorship W2562165295A5019624678 @default.
• W2562165295 hasAuthorship W2562165295A5022068541 @default.
• W2562165295 hasAuthorship W2562165295A5025865972 @default.
• W2562165295 hasAuthorship W2562165295A5035939523 @default.
• W2562165295 hasAuthorship W2562165295A5043136547 @default.
• W2562165295 hasAuthorship W2562165295A5091651670 @default.
• W2562165295 hasAuthorship W2562165295A5091653815 @default.
• W2562165295 hasConcept C121332964 @default.
• W2562165295 hasConcept C126322002 @default.
• W2562165295 hasConcept C142424586 @default.
• W2562165295 hasConcept C2776063141 @default.
• W2562165295 hasConcept C2776364478 @default.
• W2562165295 hasConcept C2776694085 @default.
• W2562165295 hasConcept C2776755627 @default.
• W2562165295 hasConcept C2777063308 @default.
• W2562165295 hasConcept C2777938653 @default.
• W2562165295 hasConcept C2778461978 @default.
• W2562165295 hasConcept C2778524551 @default.
• W2562165295 hasConcept C2778570526 @default.
• W2562165295 hasConcept C2778822529 @default.
• W2562165295 hasConcept C2778850193 @default.
• W2562165295 hasConcept C2779263901 @default.
• W2562165295 hasConcept C2779338263 @default.
• W2562165295 hasConcept C2779609412 @default.
• W2562165295 hasConcept C2779788671 @default.
• W2562165295 hasConcept C2780653079 @default.
• W2562165295 hasConcept C2781442060 @default.
• W2562165295 hasConcept C29730261 @default.
• W2562165295 hasConcept C71924100 @default.
• W2562165295 hasConcept C87355193 @default.
• W2562165295 hasConcept C90924648 @default.
• W2562165295 hasConceptScore W2562165295C121332964 @default.
• W2562165295 hasConceptScore W2562165295C126322002 @default.
• W2562165295 hasConceptScore W2562165295C142424586 @default.
• W2562165295 hasConceptScore W2562165295C2776063141 @default.
• W2562165295 hasConceptScore W2562165295C2776364478 @default.
• W2562165295 hasConceptScore W2562165295C2776694085 @default.
• W2562165295 hasConceptScore W2562165295C2776755627 @default.
• W2562165295 hasConceptScore W2562165295C2777063308 @default.
• W2562165295 hasConceptScore W2562165295C2777938653 @default.
• W2562165295 hasConceptScore W2562165295C2778461978 @default.
• W2562165295 hasConceptScore W2562165295C2778524551 @default.
• W2562165295 hasConceptScore W2562165295C2778570526 @default.
• W2562165295 hasConceptScore W2562165295C2778822529 @default.
• W2562165295 hasConceptScore W2562165295C2778850193 @default.
• W2562165295 hasConceptScore W2562165295C2779263901 @default.
• W2562165295 hasConceptScore W2562165295C2779338263 @default.
• W2562165295 hasConceptScore W2562165295C2779609412 @default.
• W2562165295 hasConceptScore W2562165295C2779788671 @default.
• W2562165295 hasConceptScore W2562165295C2780653079 @default.
• W2562165295 hasConceptScore W2562165295C2781442060 @default.
• W2562165295 hasConceptScore W2562165295C29730261 @default.
• W2562165295 hasConceptScore W2562165295C71924100 @default.
• W2562165295 hasConceptScore W2562165295C87355193 @default.
• W2562165295 hasConceptScore W2562165295C90924648 @default.
• W2562165295 hasLocation W25621652951 @default.
• W2562165295 hasOpenAccess W2562165295 @default.
• W2562165295 hasPrimaryLocation W25621652951 @default.
• W2562165295 hasRelatedWork W2043921099 @default.
• W2562165295 hasRelatedWork W2064545512 @default.
• W2562165295 hasRelatedWork W2100309290 @default.
• W2562165295 hasRelatedWork W2430561414 @default.
• W2562165295 hasRelatedWork W2559725481 @default.
• W2562165295 hasRelatedWork W2562165295 @default.
• W2562165295 hasRelatedWork W2578051247 @default.
• W2562165295 hasRelatedWork W2944533212 @default.
• W2562165295 hasRelatedWork W2979430133 @default.
• W2562165295 hasRelatedWork W2982316735 @default.
• W2562165295 isParatext "false" @default.
• W2562165295 isRetracted "false" @default.
• W2562165295 magId "2562165295" @default.
• W2562165295 workType "article" @default.